Premium
O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY
Author(s) -
Voyle Nicola,
Abi-Saab Danielle,
Klein Gregory,
Hofmann Carsten,
Delmar Paul,
Pross Nathalie,
Andjelkovic Mirjana,
Milosavljevic-Ristic Smiljana,
Martenyi Ferenc,
Fontoura Paulo,
Doody Rachelle
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2379
Subject(s) - cerebrospinal fluid , medicine , placebo , biomarker , amyloid β , pathology , gastroenterology , nuclear medicine , disease , chemistry , biochemistry , alternative medicine
doses of LY3002813 resulted in significant reductions in florbetapir F18 tracer uptake on PET by 3 months, with further reduction with repeat dosing over time. For the initial dosing cohorts, reductions in florbetapir F18 at 3 months were -11.8 (SD 21.1) centiloids after a single dose of 10 mg/kg IV (n1⁄47); -39.0 (SD 18.1) centiloids after a single dose of 20mg/kg IV (n1⁄47); and -44.5 (SD 24.3) centiloids for 10mg/kg IVadministered every two weeks (n1⁄410). In patients with up to 72 weeks of follow-up after completion of treatment, the reduced post-treatment florbetapir F18 PET SUVr levels were maintained, without returning to pre-dose baseline levels. Conclusions: LY3002813 demonstrates significant, rapid and sustained reduction in cortical amyloid plaque in Alzheimer’s patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom